The intrinsic physical and radiobiological characteristics of High Dose Rate Brachytherapy (HDR-BT) are well suited to the treatment of prostate cancer. HDR-BT was initially used as a boost to external beam brachytherapy, but has subsequently been employed as the sole treatment, which is termed HDR monotherapy. This review summarizes the clinical outcomes and toxicity results of the principal studies and discusses the radiobiological basis supporting its use.
Trial registration: ClinicalTrials.gov NCT00807820 NCT01045148 NCT01605097 NCT01655836 NCT01851018.
Keywords: Brachytherapy boost, Radiobiology.; HDR-BT; High-dose rate brachytherapy; Prostate cancer; Salvage brachytherapy.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.